Latest News

  • 15 Sep 2016

    TapImmune Announces Reverse Stock Split in Preparation for ...

    JACKSONVILLE, Florida, September 15, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today that its Board of...

    more >

  • 6 Sep 2016

    TapImmune Issues Update: Multiple Phase 2 Trials, over $9 Mi...

    JACKSONVILLE, Florida, September 6, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today issued a shareholder update...

    more >